HCV Competitive Landscape (Nov 2011) Pharmasset – BMS 2-drug Combo
{"Image DocumentName": "HCV Competitive Landscape (Nov 2011) Pharmasset \u2013 BMS 2-drug Combo", "Image ImageDescription": "simeprevir. (J&J) BI\u2019335. (BI) daclatasvir. BMS. ABT 2-3-Drug Combo. ABT 2-3-Drug Combo. PSI7977. (Pharmasset) GILD2 or 3-Drug Combo. mericitabine. (Roche) alisporivir. (NVS) GILD 2-3-Drug Combo. ABT450/r. VRTX 2-Drug Combo. Pharmasset 2-drug. Combo? ABT267. JNJ Pharmasset. 2-Drug Combo. Roche 2-Drug Combo. BI 2-Drug Combo. ABT333. BMS 2-Drug Combo. GILD GS9451. Pharmasset \u2013 BMS 2-drug Combo. GILD GS5885. Assumes 2 or 3 drug DAA with SOC for shorter duration or with ribavirin for an all oral regimen. GILD tegobuvir. MK (Japan Only) MK5172. MRK NS5A. PI. NNI. NS5A. NI. Other.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}